Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

Inclusion Criteria: * Patients must have stage IV, microscopically-confirmed carcinoma of the breast with histologic slides and/or blocks available for review. * Patients must have relapse or progression while receiving, or within 12 months of having received, anthracycline-containing (doxorubicin or mitoxantrone) regimen as either adjuvant treatment or therapy for advanced breast cancer. Prior Taxol by 3- or 24-hour infusion is permitted. Patients who have received a maximum dose of anthracycline (greater than 450 mg/m2) are also eligible. * Patients must have measurable (bidimensionally) or evaluable disease. * Patients must be 18 or more years of age. * Patients must have a Karnofsky Performance Status greater than or equal to 70% at screen and on the first day of treatment. * Patients must have a life expectancy of more than 16 weeks. * Prior irradiation is permitted, provided that prior irradiation does not exceed 25% of the estimated bone marrow volume and provided that measurable/evaluable disease exists outside the radiation field OR there must be histologic proof of progressive disease within a radiation field. * Informed consent must be obtained prior to registration. * Patients must be more than 2 weeks from prior surgery; more than 3 weeks from radiation therapy to the pelvis, spine or long bones; more than 3 weeks from prior chemotherapy (more than 6 weeks for mitomycin C or nitrosureas), or more than 2 weeks from prior hormonal therapy. * All patients must have appropriate central venous access. Exclusion Criteria: Patients are excludes if their: * Granulocyte count is less than 1,500/mm3. * Platelet count is less than 100,000/mm3. * Hemoglobin is less than 9 gm/dl. * Creatinine is greater than 2.0 mg/dl. * Total bilirubin is greater than ULN (institutional upper limit of normal).. * SGOT (AST) and/or SGPT (ALT) is greater than 1.5 x ULN concomitant with alkaline phosphatase greater than 2.5 x ULN. Patients are excluded if they are: * In visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases. * Medically unstable. * Pregnant or lactating. Patients are excluded if they have: * Uncontrolled CNS disease. * Pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer. * Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol. * Prior therapy with Navelbine. * Sensitivity to E. Coli-derived proteins.